Detail akcie Aspen Pharmacare online

Business Summary: Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Aspen Pharmacare Holdings Ltd revenues decreased 3% to RAN43.36B. Net loss totaled RAN1.08B vs. income of RAN4.4B. Revenues reflect Manufacturing segment decrease of 64% to RAN11.15B, Developed Europe segment decrease of 17% to RAN14.68B, Australasia segment decrease of 6% to RAN6.31B. Net loss reflects Impairment of intangible assets increase from RAN2.42B to RAN5.3B (expense).